Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients

Affiliations

¹ Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacy Practice and Science Department, College of Pharmacy, University of Arizona, Tucson, AZ, USA. Electronic address: keljaaly@kau.edu.sa.
² Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Comment

Khalid Eljaaly et al. Travel Med Infect Dis. 2020 Nov-Dec.

. 2020 Nov-Dec:38:101749.

doi: 10.1016/j.tmaid.2020.101749. Epub 2020 May 28.

¹ Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacy Practice and Science Department, College of Pharmacy, University of Arizona, Tucson, AZ, USA. Electronic address: keljaaly@kau.edu.sa.
² Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

No abstract available

Comment on

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. Cao B, et al. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187464 Free PMC article. Clinical Trial.

1. Al-Tawfiq J.A., Al-Homoud A.H., Memish Z.A. Remdesivir as a possible therapeutic option for the COVID_19. Trav Med Infect Dis. 2020 Mar 5:101615. doi: 10.1016/j.tmaid.2020.101615. - DOI - PMC - PubMed
1. Cao B., Wang Y., Wen D. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–1799. - PMC - PubMed
1. Lopinavir/ritanavir (Kaletra®) AbbVie; North Chicago, IL: 2019. [prescribing information)]
1. Best B.M., Capparelli E.V., Rossi S.S. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):385–391. - PMC - PubMed